Literature DB >> 15131400

The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.

Inbar Gal1, Ruth Gershoni Baruch, Daniel Haber, Efrat Dagan, Shlomit Eisenberg-Barzilai, Jamal Zidan, Eitan Friedman.   

Abstract

Few mutations have been described in BRCA1 and BRCA2 in high-risk non-Ashkenazi Jews. In a Libyan family the 1100delAT BRCA1 mutation was detected and the 8765delAG BRCA2 mutation was previously described in two Jewish-Yemenite-families. In this study, the rate of these mutations in high-risk Jews of North African and Yemenite origin was assessed, and the BRCA1 -linked haplotype of Jewish and non-Jewish 1100delAT mutation carriers were compared. Genotyping included 64 high-risk Yemenite women (tested only for the BRCA 2 mutation) and 147 high-risk North African women, tested for both mutations. PCR amplification was followed by either restriction enzyme digestion or DGGE or dHPLC analyses and direct sequencing. For haplotyping, 5 BRCA1 -linked markers were used. Neither the 1100delAT BRCA1 nor the 8765delAG BRCA2 mutations were detected in any non-Ashkenazi individual. The haplotype of the non-Jewish 1100delAG mutation carrier differed from that of the Jewish-Libyan mutation carriers. We conclude that both1100delAT BRCA1 and 8765delAG BRCA2 mutations occur rarely in high-risk non-Ashkenazi Jews, and while the latter seems to be a founder mutation in some populations, the former occurs on a different background in ethnically diverse families.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131400     DOI: 10.1023/B:FAME.0000026837.32470.b4

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  26 in total

1.  Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families.

Authors:  R B Barkardottir; L Sarantaus; A Arason; P Vehmanen; P O Bendahl; T Kainu; K Syrjäkoski; R Krahe; P Huusko; S Pyrhönen; K Holli; O P Kallioniemi; V Egilsson; J Kere; H Nevanlinna
Journal:  Eur J Hum Genet       Date:  2001-10       Impact factor: 4.246

2.  Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families.

Authors:  A P Manning; D Abelovich; P Ghadirian; J A Lambert; D Frappier; D Provencher; A Robidoux; T Peretz; S A Narod; A M Mes-Masson; W D Foulkes; T Wang; K Morgan; T M Fujiwara; P N Tonin
Journal:  Hum Hered       Date:  2001       Impact factor: 0.444

3.  Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.

Authors:  S L Neuhausen; A K Godwin; R Gershoni-Baruch; E Schubert; J Garber; D Stoppa-Lyonnet; E Olah; B Csokay; O Serova; F Lalloo; A Osorio; M Stratton; K Offit; J Boyd; M A Caligo; R J Scott; A Schofield; E Teugels; M Schwab; L Cannon-Albright; T Bishop; D Easton; J Benitez; M C King; B A Ponder; B Weber; P Devilee; A Borg; S A Narod; D Goldgar
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

4.  Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

Authors:  B Modan; P Hartge; G Hirsh-Yechezkel; A Chetrit; F Lubin; U Beller; G Ben-Baruch; A Fishman; J Menczer; J P Struewing; M A Tucker; S Wacholder
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

5.  BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling.

Authors:  G Palmieri; G Palomba; A Cossu; M Pisano; M F Dedola; M G Sarobba; A Farris; N Olmeo; A Contu; A Pasca; M P Satta; I Persico; A A Carboni; P Cossu-Rocca; M Contini; J Mangion; M R Stratton; F Tanda
Journal:  Ann Oncol       Date:  2002-12       Impact factor: 32.976

6.  Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis.

Authors:  E M Rohlfs; W G Learning; K J Friedman; F J Couch; B L Weber; L M Silverman
Journal:  Clin Chem       Date:  1997-01       Impact factor: 8.327

7.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Authors:  J P Struewing; D Abeliovich; T Peretz; N Avishai; M M Kaback; F S Collins; L C Brody
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

8.  Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.

Authors:  S L Neuhausen; S Mazoyer; L Friedman; M Stratton; K Offit; A Caligo; G Tomlinson; L Cannon-Albright; T Bishop; D Kelsell; E Solomon; B Weber; F Couch; J Struewing; P Tonin; F Durocher; S Narod; M H Skolnick; G Lenoir; O Serova; B Ponder; D Stoppa-Lyonnet; D Easton; M C King; D E Goldgar
Journal:  Am J Hum Genet       Date:  1996-02       Impact factor: 11.025

9.  Identification of a founder BRCA2 mutation in Sardinia.

Authors:  M Pisano; A Cossu; I Persico; G Palmieri; A Angius; G Casu; G Palomba; M G Sarobba; P C Rocca; M F Dedola; N Olmeo; A Pasca; M Budroni; V Marras; A Pisano; A Farris; G Massarelli; M Pirastu; F Tanda
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

10.  An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews.

Authors:  L Theodor; R Bar-Sade; A Kruglikova; G Ben-Baruch; S Risel; R Shiri-Sverdlov; G Hirsh Yechezkel; B Modan; M Z Papa; G Rechavi; E Friedman
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more
  2 in total

1.  The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer.

Authors:  Chuan-Gui Song; Zhen Hu; Jiong Wu; Jian-Min Luo; Zhen-Zhou Shen; Wei Huang; Zhi-Ming Shao
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-12       Impact factor: 4.553

2.  A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing.

Authors:  D Purnomosari; D K Paramita; T Aryandono; G Pals; P J van Diest
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.